Latest | Instant news on finance, ETFs, IPOs etc. _第25页 | NewTimeSpace

07:32

【JIANGSU EXPRESS (00177.HK): Injects RMB 600 Million into Clean Energy Subsidiary】NewTimeSpace News: On 28 August 2026, JIANGSU EXPRESS (00177.HK) announced Board approval of a RMB 600 million capital injection into its clean energy subsidiary, to be paid over five years (RMB 40 million expected in 2026), raising its registered capital from RMB 2.0 billion to RMB 2.6 billion, with proceeds for fishery/crab-pond photovoltaic and wind power projects.

Tag： JIANGSU EXPRESS 00177.HK Capital Injection

22:44

【Transwarp Technology passes HKEX hearing; China's fifth-largest AI infrastructure software provider by revenue】NewTimeSpace News: On 27 August 2026, Transwarp Technology (Shanghai) Co., Ltd. passed the HKEX listing hearing, with Haitong International as sole sponsor; by revenue, the Company is China's fifth-largest AI infrastructure software provider (2.7% market share in 2025) and the largest independent service provider, and the first database enterprise globally to pass TPC-DS audit; its products cover big data platforms, distributed databases, AI platforms and knowledge platforms, serving over 1,800 customers including 105 Fortune China 500 enterprises, with repeat purchase revenue from existing customers averaging over 70% of total revenue.

Tag： Transwarp Technolog IPO pass the listing hearing

22:29

【Shanghai Vision Star Media files for HKEX listing with SPDB International as sole sponsor; China's largest brand-IP content marketing provider】NewTimeSpace News: On 27 August 2026, Shanghai Vision Star Media Co., Ltd. filed a listing application with HKEX, with SPDB International as sole sponsor; by 2025 revenue, the Company was the fifth largest integrated marketing service provider and the largest brand-IP content marketing service provider in China; revenue reached RMB 8.3718 billion in 2025 (CAGR of 15.8% from 2023), serving over 2,000 clients including 69 China Fortune 500 enterprises; the Company has built the "Xinghe AI Full-Link Workbench" with peak daily token usage of approximately 1.7 billion; no stock code has been assigned at the filing stage.

Tag： Vision Star Media IPO file a listing application

22:21

【SIHUAN PHARM (00460.HK): Repurchases 10 million shares for about HKD 8.111 million; H1 net profit up 221% year on year】NewTimeSpace News: On 27 August 2026, SIHUAN PHARM (00460.HK) announced that, pursuant to the general buyback mandate, it repurchased 10,000,000 shares at an average price of HKD 0.8111 per share, for a total of approximately HKD 8.111 million, representing approximately 0.1096% of issued shares (excluding treasury) and to be held as treasury shares; the Group reported H1 2026 revenue of RMB 1.161 billion (up 1.3%) and net profit of RMB 212 million (up 221%), with medical aesthetics revenue of RMB 693 million (up 18.5%).

Tag： SIHUAN PHARM 00460.HK Share Buyback

22:19

【CHINA VANKE (02202.HK): Newly disclosed unsettled litigation and arbitration involving about RMB 12.041 billion, equivalent to 10.30% of net assets】NewTimeSpace News: On 27 August 2026, CHINA VANKE (02202.HK) announced that, from 1 March 2026 to 31 July 2026, the Company and its controlling subsidiaries recorded newly unsettled litigation and arbitration matters involving approximately RMB 12.041 billion, equivalent to 10.30% of the absolute value of the latest audited net assets; four cases each exceeded RMB 300 million, totaling RMB 4.050 billion, and the impact of some cases on the Company's profits remains uncertain.

Tag： CHINA VANKE 02202.HK Litigation

22:16

【GUSHENGTANG (02273.HK): Subsidiary to acquire 100% equity of three TCM clinics in Malaysia, expanding overseas offline network】NewTimeSpace News: On 27 August 2026, GUSHENGTANG (02273.HK) announced that its subsidiary Gushengtang Malaysia has entered into sale and purchase contracts to acquire the 100% equity interests of three TCM medical institutions in Malaysia (YC TCM SEGAR, YC TCM and SWS Medical) to expand its overseas offline network and create synergies; the consideration was determined after fair negotiation and will be funded by placing/convertible bond proceeds and idle funds; the acquisition does not constitute a connected or discloseable transaction and is subject to conditions precedent.

Tag： GUSHENGTANG 02273.HK acquisition

22:14

【DRAGON RISE GP (06829.HK): Enters blockchain agency agreement to issue asset-backed tokenized notes; initial tranche capped at HKD 30 million】NewTimeSpace News: On 27 August 2026, DRAGON RISE GP (06829.HK) voluntarily announced that its wholly-owned subsidiary DRNE Next Mobility has entered into an agreement with a blockchain service provider to issue tokenized notes secured by physical assets (battery-swap electric taxi fleet and income from swap infrastructure) on Ethereum and Solana; the reserved quota is HKD 100 million with an initial tranche cap of HKD 30 million, a minimum subscription of HKD 400,000, a two-year lock-up, and a target return of 4% fixed interest plus up to 6% performance-linked interest per annum.

Tag： DRAGON RISE GP 06829.HK Tokenized Notes

22:05

【XIABUXIABU (00520.HK): He Guangqi steps down as CEO and re-designated as non-executive director; Feng Huihuang appointed new CEO】NewTimeSpace News: On 27 August 2026, XIABUXIABU (00520.HK) announced that Mr. He Guangqi will step down as CEO and be re-designated from executive to non-executive director with effect from 28 August 2026, continuing as Chairman with an annual director's fee of HKD 1,220,000; Mr. Feng Huihuang will succeed him as CEO with annual remuneration of RMB 984,000, temporarily also holding the finance role; the change brings the Company into compliance with Code Provision C.2.1.

Tag： XIABUXIABU 00520.HK Board Change

21:58

【ABLE DIGITAL (02687.HK): Proposes H-share full circulation; 4,713,900 domestic unlisted shares to be converted into H shares】NewTimeSpace News: On 27 August 2026, ABLE DIGITAL (02687.HK) announced that the Board has approved the proposed H-share full circulation, converting 4,713,900 domestic unlisted shares held by shareholders into H shares, representing approximately 7.0708% of the issued share capital; the conversion remains subject to CSRC filing and HKEX approval, no general meeting is required, and the Company has not yet submitted the filing application.

Tag： ABLE DIGITAL 02687.HK H-share full circulation

21:55

【TYK MEDICINES-B (02410.HK): Dovatinib mesylate tablets (TY-9591) granted conditional approval as first-line treatment for EGFR-mutant NSCLC with CNS metastases】NewTimeSpace News: On 27 August 2026, TYK MEDICINES-B (02410.HK) announced that its self-developed next-generation EGFR-TKI dovatinib mesylate tablets (TY-9591) have been granted conditional NMPA approval for the first-line treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR 19del or L858R mutations with CNS metastases; the drug is a differentiated deuterated innovation derived from osimertinib, and the Company has initiated multiple monotherapy and combination studies around the product.

Tag： TYK MEDICINES-B 02410.HK Clinical Progress

21:50

【ZHENRO SERVICES (06958.HK): Appoints Mr. Wang Yi as executive director with basic salary of RMB 680,000 per annum】NewTimeSpace News: On 27 August 2026, ZHENRO SERVICES (06958.HK) announced the appointment of Mr. Wang Yi, aged 44 and currently the Company Secretary and CFO, as an executive director with effect from the same day, with the appointment lasting until the conclusion of the next annual general meeting and a basic salary of RMB 680,000 per annum.

Tag： ZHENRO SERVICES 06958.HK Appointment

21:48

【IMMUNEONCO-B (01541.HK): First patient dosed in Phase II trial of IMM2510 plus IMM27M as first-line treatment for advanced HCC】NewTimeSpace News: On 27 August 2026, IMMUNEONCO-B (01541.HK) announced that the first patient has been dosed in the Phase II trial (IMM2510-HCC-201) of IMM2510 plus IMM27M as first-line treatment for advanced HCC; the Phase Ib trial has determined the RP2D with expansion studies in esophageal squamous cell carcinoma and other solid tumors, and 6 evaluable patients in dose escalation achieved an ORR of 50%; the combination achieves synergistic coverage of PD-L1, VEGF and CTLA-4, with a Rule 18A.05 warning statement included.

Tag： IMMUNEONCO-B 01541.HK Clinical Trial

21:42

【COOLPAD GROUP (02369.HK): Subsidiary sells 248 MSTR call options for total premium of approximately HKD 557,962】NewTimeSpace News: On 27 August 2026, COOLPAD GROUP (02369.HK) announced that its wholly-owned subsidiary Digital Tech sold 248 call options covering 24,800 MSTR shares for a total premium of USD 71,442 (approximately HKD 557,962), with a strike price of USD 140.00 per share and expiry on 11 September 2026; if all options are exercised, the Group expects to recognize a gain of approximately USD 1.16 million, and the sale constitutes a discloseable transaction exempt from shareholders' approval.

Tag： COOLPAD GROUP 02369.HK Option Sale

19:53

【SHIMAO GROUP (00813.HK): Winding-up petition filed by Guotong Trust; first hearing scheduled for 11 November】NewTimeSpace News: On 27 August 2026, SHIMAO GROUP (00813.HK) announced that Guotong Trust had filed a winding-up petition against the Company with the High Court, relating to judgment debts of RMB 2,497,885,817 arising from four judgments by Mainland courts, with the first hearing fixed for 11 November 2026; no winding-up order has been issued, the Company will resolutely oppose the petition, and the announcement cautioned on the effects of Section 182 of the Companies Ordinance and potential HKSCC service suspensions.

Tag： SHIMAO GROUP 00813.HK winding-up petition

19:50

【SHIMAO SERVICES (00873.HK): Winding-up petition filed against holding company Shimao Group over judgment debts of about RMB 2.50 billion】NewTimeSpace News: On 27 August 2026, SHIMAO SERVICES (00873.HK) announced that its holding company Shimao Group had received a winding-up petition filed by Guotong Trust relating to judgment debts of RMB 2,497,885,817 arising from four judgments by Mainland courts; no winding-up order has been issued by the High Court, and the Board believes the petition will have no material impact on the Group's financial performance and operations.

Tag： SHIMAO SERVICES 00873.HK winding-up petition

19:45

【FOSUN PHARMA (02196.HK): Licensed drug weliteitumab injection (GR1803) granted conditional approval for relapsed or refractory multiple myeloma】NewTimeSpace News: On 27 August 2026, FOSUN PHARMA (02196.HK) announced that GR1803 injection (weliteitumab injection; trade name Weikenuo), licensed by its controlling subsidiary Yaoyou Pharmaceutical, has been granted conditional NMPA approval for adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy; the drug is a BCMA×CD3 bispecific antibody in a 20mg (2ml) per vial specification classified as Class 1 therapeutic biologics, with global sales of same-target drugs reaching approximately USD 1.139 billion in 2025, and an MAH transfer will subsequently be advanced.

Tag： FOSUN PHARMA 02196.HK Clinical Progress

19:41

【CHENGDU EXPWAY (01785.HK): Non-executive director Wu Haiyan retires; board gender diversity temporarily falls short of Listing Rules】NewTimeSpace News: On 27 August 2026, CHENGDU EXPWAY (01785.HK) announced that non-executive director Ms. Wu Haiyan resigned with immediate effect due to retirement, also ceasing her roles on three board committees; the Board proposed appointing Ms. Jiang Na as a non-executive director, subject to shareholders' approval; following Ms. Wu's departure, the audit committee fell below three members and the board's gender diversity no longer complies with the Listing Rules, with the Company aiming to fill vacancies within three months.

Tag： CHENGDU EXPWAY 01785.HK resignation

19:38

【HK ROBOTICS (00370.HK): Three core objectives of Danta cooperation basically achieved; robotics and computing power revenue of HKD 169.6 million】NewTimeSpace News: On 27 August 2026, HK ROBOTICS (00370.HK) announced the latest progress of its cooperation with Danta Robotics: three core objectives including the establishment of the joint venture, IP licensing and operation team formation have been basically achieved, with the exclusive license for the Danta Cloud Brain expiring in September 2028; robotics and computing power revenue for the year ended 31 March 2026 was approximately HKD 169.6 million, of which about 83% related to products using Danta's licensed IP; the 2025 revenue target was not fully achieved due to delays, with the parties negotiating adjustments and the Group seeking to reduce its 49% stake in the joint venture; the Group is independently developing the "Hong Kong Robotics Cloud Brain" expected to be completed before September 2028, after which license fees will no longer be payable.

Tag： HK ROBOTICS 00370.HK strategic cooperation Humanoid Robot

19:32

【ZOOMLION(01157.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 2.1 billion, YoY decrease of 23.65%】NewTimeSpace News: August 27, 2026, ZOOMLION(01157.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 27.14 billion, increased by 9.17% YoY

Tag： ZOOMLION 01157.HK Profit declined

19:32

【JW THERAP-B(02126.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 50.43 million, loss narrowed by 81.13% YoY】NewTimeSpace News: August 27, 2026, JW THERAP-B(02126.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 111.35 million, increased by 4.71% YoY.

Tag： JW THERAP-B 02126.HK loss narrowed

Scan QR Code

Download App